Impact Sibutramine Therapy in Children with Hypothalamic Obesity or Obesity with Aggravating Syndromes
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Behavioral treatment of children suffering from hypothalamic obesity or uncomplicated obesity in combination with syndromes that aggravate this condition has proven to be ineffective. The combination of comorbidities and severe obesity lower the quality of these children's lives drastically. The present goal was to determine whether treatment with sibutramine has a beneficial effect on such children. DESIGN AND SUBJECTS: A double-blind, placebo-controlled, cross-over study (20 + 20 wk), followed by a 6-month open phase, was performed. The primary indicator of efficacy was the body mass index (BMI) sd score (SDS) value, which was analyzed using an ANOVA repeated-measures design [intention to treat (ITT)]. The 50 children (7-20 yr of age) involved included 22 with hypothalamic obesity and 28 with uncomplicated obesity plus aggravating syndromes. Forty-five patients completed the first phase, and 42 participated in the entire study. RESULTS: The group that initially received the placebo demonstrated an insignificant decrease (-0.06) in BMI SDS during this treatment but a significant decrease (-0.68; P < 0.001) when treated with sibutramine. The other group demonstrated a reduction in their BMI SDS of -0.72 during administration of sibutramine and a rebound of +0.43 when placed on the placebo (P < 0.001 in both cases). The response of children with hypothalamic obesity was also significant but was less pronounced than that of children with nonhypothalamic obesity. During the open phase, a continuous reduction in weight was observed. The treatment was tolerated well. CONCLUSION: The clinically and statistically significant weight reduction caused by sibutramine in this short-term study indicates that treatment of hypothalamic and syndromal obesity with this drug may be beneficial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other medications such as sibutramine, a norepinephrine and serotonin inhibitor, lorcaserin, a serotonin 2C receptor agonist, and beloranib, a methionine aminopeptidase 2 inhibitor, were discontinued due to significant adverse events of thromboembolism and other safety concerns (140).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [140]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Interventions for treating obesity in children
Oude Luttikhuis, H., Baur, L., Jansen, H., Shrewsbury, V. A., O'Malley, C., Stolk, R. P., & Summerbell, C. D. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001872.pub2 · Cited by 1,531 · cited 1×
“are often ignored in reviews on treatment of obesity (12, 13).”
BackgroundRetractedObesity in children and young people: a crisis in public health
Lobstein, T., Baur, L., & Uauy, R. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00133.x · Cited by 3,801 · cited 1×
“The pronounced prevalence of obesity at a young age (1), in combination with increasing awareness of the associated risk for morbidity later in life (2), has motivated both medical societies and health authorities to devote more effort to the development of effective strategies for prevention and treatment of this dis…”
BackgroundCraniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up
Karavitaki, N., Brufani, C., Warner, J. T., Adams, C. B. T., Richards, P., Ansorge, O., Shine, B., Turner, H. E., & Wass, J. A. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02231.x · Cited by 633
Research works printed but not linked: 22
- Weiss, 2004, Obesity and the metabolic syndrome in children and adolescents., N Engl J Med, 350, 2362, 10.1056/NEJMoa031049 · DOI · Paper page
- Dietz, 2005, Clinical practice. Overweight children and adolescents., N Engl J Med, 352, 2100, 10.1056/NEJMcp043052 · DOI · Paper page
- Lindgren, 2000, Eating behavior in Prader-Willi syndrome, normal weight, and obese control groups., J Pediatr, 137, 50, 10.1067/mpd.2000.106563 · DOI
- Sorva, 1988, Children with craniopharyngioma. Early growth failure and rapid postoperative weight gain., Acta Paediatr Scand, 77, 587, 10.1111/j.1651-2227.1988.tb10705.x · DOI · Paper page
- Geffner, 2004, Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database)., J Clin Endocrinol Metab, 89, 5435, 10.1210/jc.2004-0667 · DOI · Paper page
- Farooqi, 2005, Monogenic obesity in humans., Annu Rev Med, 56, 443, 10.1146/annurev.med.56.062904.144924 · DOI · Paper page
- Bray, 1984, Syndromes of hypothalamic obesity in man., Pediatr Ann, 13, 525
- Muller, 2005, Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma., Childs Nerv Syst, 21, 975, 10.1007/s00381-004-1124-y · DOI
- Poretti, 2004, Outcome of craniopharyngioma in children: long-term complications and quality of life., Dev Med Child Neurol, 46, 220, 10.1111/j.1469-8749.2004.tb00476.x · DOI · Paper page
- Ryan, 1995, Sibutramine: a novel new agent for obesity treatment, Obes Res, 3, 553S, 10.1002/j.1550-8528.1995.tb00227.x · DOI · Paper page
- Berkowitz, 2003, Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial., JAMA, 289, 1805, 10.1001/jama.289.14.1805 · DOI · Paper page
- Godoy-Matos, 2005, Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study., J Clin Endocrinol Metab, 90, 1460, 10.1210/jc.2004-0263 · DOI · Paper page
- Berkowitz, 2006, Effects of sibutramine treatment in obese adolescents: a randomized trial., Ann Intern Med, 145, 81, 10.7326/0003-4819-145-2-200607180-00005 · DOI · Paper page
- Daniels, 2007, Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study, Pediatrics, 120, e147, 10.1542/peds.2006-2137 · DOI · Paper page
- Garcia-Morales, 2006, Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial., Clin Ther, 28, 770, 10.1016/j.clinthera.2006.05.008 · DOI
- Van Mil, 2007, The effect of sibutramine on energy expenditure and body composition in obese adolescents., J Clin Endocrinol Metab, 92, 1409, 10.1210/jc.2006-0264 · DOI
- Rolland-Cachera, 1982, Adiposity indices in children., Am J Clin Nutr, 36, 178, 10.1093/ajcn/36.1.178 · DOI · Paper page
- Cole, 2000, Establishing a standard definition for child overweight and obesity worldwide: international survey., BMJ, 320, 1240, 10.1136/bmj.320.7244.1240 · DOI · Paper page
- Yanovski, 2002, Obesity., N Engl J Med, 346, 591, 10.1056/NEJMra012586 · DOI · Paper page
- Jeanrenaud, 1985, An hypothesis on the etiology of obesity: dysfunction of the central nervous system as a primary cause., Diabetologia, 28, 502, 10.1007/BF00281984 · DOI
- Lustig, 2003, Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial., J Clin Endocrinol Metab, 88, 2586, 10.1210/jc.2002-030003 · DOI · Paper page
- Lustig, 1999, Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist., J Pediatr, 135, 162, 10.1016/S0022-3476(99)70017-X · DOI · Paper page
Cited by
Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,282
Müller, H. L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1115 · Cited by 401
Response of Severely Obese Children and Adolescents to Behavioral Treatment
Danielsson, P., Kowalski, J., Ekblom, Ö., & Marcus, C. (2012) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/2013.jamapediatrics.319 · Cited by 291
Self-citationIepsen, E. W., Zhang, J., Thomsen, H. S., Hansen, E. L., Hollensted, M., Madsbad, S., Hansen, T., Holst, J. J., Holm, J.-C., & Torekov, S. S. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.008 · Cited by 156
van Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Metadata
- Authors
- Danielsson, P., Janson, A., Norgren, S., & Marcus, C.
- Affiliations
- Department of Paediatrics, Clintec, and the National Childhood Obesity Centre, Karolinska Institutet, Karolinska University Hospital, S-141 86 Stockholm, Sweden
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-11-01
- Volume
- 92
- Issue
- 11
- Pages
- 4101-4106
- ISSN
- 0021-972X
- 1945-7197
- Cited by
- 63
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact Sibutramine Therapy in Children with Hypothalamic Obesity or Obesity with Aggravating Syndromes. https://app.cochat.ai/papers/10.1210/jc.2007-0826
- The paper
- Danielsson, P., Janson, A., Norgren, S., & Marcus, C. (2007). Impact Sibutramine Therapy in Children with Hypothalamic Obesity or Obesity with Aggravating Syndromes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2007-0826
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.